Compare
ResMed Inc vs Solventum Corp vs West Pharmaceutical Services Inc vs Baxter International Inc
| Latest fiscal year | ResMed Inc RMD | Solventum Corp SOLV | West Pharmaceutical Services Inc WST | Baxter International Inc BAX |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.65B | $8.32B | $3.07B | $11.24B |
| Revenue growth (YoY) | +9.9% | +0.9% | +6.3% | +5.7% |
| Gross margin | 61.1% | 53.5% | 35.9% | 30.1% |
| Operating margin | 33.4% | 26.2% | 19.0% | -2.7% |
| Net margin | 26.9% | 18.7% | 16.1% | -8.5% |
| Net income | $1.52B | $1.56B | $493.70M | -$957.00M |
| EPS (Diluted) | $10.43 | $8.88 | $6.79 | -$1.87 |
| Operating cash flow | $1.81B | $369.00M | $754.80M | $845.00M |
| Free cash flow | $1.65B | -$10.00M | $468.90M | $332.00M |
| Cash & equivalents | $1.47B | $878.00M | $791.30M | $1.97B |
| Total assets | $8.97B | $14.29B | $4.27B | $20.05B |
| Total liabilities | $2.38B | $9.24B | $1.09B | $13.95B |
| Shareholders' equity | $6.59B | $5.05B | $3.18B | $6.10B |
| Return on year-end equity | 23.1% | 30.8% | 15.5% | -15.7% |
| Shares outstanding | 144.24M | 173.49M | 72.00M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | ResMed Inc | Solventum Corp | West Pharmaceutical Services Inc | Baxter International Inc |
|---|---|---|---|---|
| Latest | $5.65B Ended 2026-06-30 | $8.32B Ended 2025-12-31 | $3.07B Ended 2025-12-31 | $11.24B Ended 2025-12-31 |
| 1 year earlier | $5.15B Ended 2025-06-30 | $8.25B Ended 2024-12-31 | $2.89B Ended 2024-12-31 | $10.64B Ended 2024-12-31 |
| 2 years earlier | $4.69B Ended 2024-06-30 | $8.20B Ended 2023-12-31 | $2.95B Ended 2023-12-31 | $10.36B Ended 2023-12-31 |
| 3 years earlier | $4.22B Ended 2023-06-30 | $8.13B Ended 2022-12-31 | $2.89B Ended 2022-12-31 | $10.06B Ended 2022-12-31 |
| 4 years earlier | $3.58B Ended 2022-06-30 | n/a | $2.83B Ended 2021-12-31 | $12.15B Ended 2021-12-31 |